Financial Data and Key Metrics Changes - The company reported Q3 revenue of $185 million, reflecting a 10% year-on-year growth and a 2% beat from the high end of guidance [4][5] - Adjusted EBITDA margin for Q3 was 60%, amounting to $111 million, which was 7% above the high end of guidance [5][12] - Non-GAAP gross margin for Q3 was 91%, down from 93% in the prior year, attributed to increased AI infrastructure investments [12][13] - Free cash flow generated in Q3 was $58.5 million, with cash, cash equivalents, and marketable securities totaling $735 million at the end of the quarter [13][14] Business Line Data and Key Metrics Changes - The company surpassed 3 million registered members, with over 85% of US physicians and two-thirds of NPs and PAs on the platform [5][6] - Unique active users for workflow tools reached a record 720,000 in Q3, marking the largest sequential gain ever [5][6] - Over 300,000 unique prescribers utilized AI products in Q3, with DocsGPT users querying an average of 4 times a week [8][9] Market Data and Key Metrics Changes - The company expects the healthcare and pharma digital advertising market to grow roughly 5% in calendar 2026 [20][22] - The net revenue retention rate was 112% on a trailing twelve-month basis, with top 20 customers showing a higher retention rate of 117% [12][13] Company Strategy and Development Direction - The company aims to strengthen its AI-powered digital platform for doctors, focusing on building trust through its Peer Check program [10][11] - The strategy includes investing in AI infrastructure and development while maintaining adjusted EBITDA margins of 50% or greater [15][18] - The company plans to commercialize its AI tools later in the year, tapping into clients' innovation and upsell budgets [18][44] Management's Comments on Operating Environment and Future Outlook - Management noted short-term industry-wide policy headwinds affecting client budgets, particularly due to recent policy changes [16][17] - Despite Q3 outperformance, the company anticipates a slower start to calendar 2026 but expects to end the year with significantly better growth [17][50] - The company is optimistic about the release of previously unreleased client funds and strong inbound demand for AI engagement [18][50] Other Important Information - The company repurchased $196.8 million worth of shares during Q3 and has a new $500 million open-ended repurchase authorization [14] - The company has over 10,000 U.S. physician experts reviewing clinical answers, enhancing the trustworthiness of its AI tools [10][11] Q&A Session Summary Question: What is the growth rate for the market in calendar year 2026? - Management expects the market to grow roughly 5% in calendar 2026, with MFN agreements impacting client budget deployments [20][22][25] Question: How does the company view AI monetization opportunities? - The company sees a large opportunity in paid search and plans to enter the market with commercial AI products later this year [58] Question: What is the strategy regarding AI infrastructure costs? - The company acknowledges that there will be costs without associated revenue for a few quarters but believes these investments are worthwhile for future growth [44][45] Question: How is the company addressing talent retention in a competitive environment? - The company is focusing on retaining mission-driven talent and offering stock grants to keep key personnel engaged [76][77] Question: What are the expectations for the mid-year upsell season? - Management believes that as client funds are released, there will be opportunities for stronger upsell during the mid-year season [40][41]

BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report fourth quarter and full year 2025 operating results after stock market trading hours on Thursday, Feb. 12. Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business u ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $314 million, a 2% increase from Q4 2024 and a 1% increase from the previous quarter [14] - Full year 2025 total revenue reached $1.185 billion, compared to $1.112 billion in 2024 [19] - Non-GAAP gross margin for Q4 2025 was 43.2%, down from 47.4% in Q4 2024 [15] - GAAP earnings per share for Q4 2025 was a loss of $0.05, compared to a profit of $0.34 in Q4 2024 [16] - Full year 2025 non-GAAP earnings per share was $1.62, down from $1.71 in 2024 [20] Business Line Data and Key Metrics Changes - Q4 2025 product revenue was $180 million, a decrease of 1% compared to Q4 2024, while service revenue was $134 million, an increase of 8% from Q4 2024 [15] - Full year 2025 product revenue was $666 million, compared to $631 million in 2024, and service revenue was $519 million, compared to $482 million in 2024 [19] Market Data and Key Metrics Changes - Annual recurring revenue (ARR) exited Q4 2025 at $636 million, a 10% increase from the 2024 exit rate of $580 million [18] - Product bookings for full year 2025 were $535 million, above the midpoint of guidance [18] - Product backlog as of December 31, 2025, was $640 million, down 1% compared to the 2024 exit [18] Company Strategy and Development Direction - The company aims to expand its market presence, scale recurring revenue, and accelerate its technology platform [5] - The introduction of Titan XT is a key part of the strategy to unify automation and intelligence in medication management [6] - The company is focused on transitioning to an end-to-end medication management platform technology company [4] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the momentum coming out of 2025, driven by customer demand and the introduction of Titan XT [11] - There is some uncertainty regarding regulations and tariffs, but overall hospital fundamentals are strong [11] - The company anticipates continued growth in 2026, with guidance for total revenue between $1.215 billion and $1.255 billion [26] Other Important Information - The company reported a decrease in cash and cash equivalents to $197 million as of December 31, 2025, down from $369 million in 2024, primarily due to debt repayment and stock repurchase [16][17] - The company achieved HITRUST CSF i1 certification for its OmniSphere platform, demonstrating commitment to cybersecurity [9] Q&A Session Summary Question: Insights on product booking expectations and the Titan cycle - Management believes the refresh cycle opportunity exceeds $2.5 billion and expects a similar rollout over the next 8 years [36][37] Question: Incremental investments around sales force and marketing - Management confirmed investments in the sales force and clinical education to capitalize on market opportunities [41][44] Question: Feedback from customers on XT Extend and Titan - Customers with XT Extend can still access cloud capabilities, and the company is engaging all customers with paths to the cloud [48] Question: Mitigation of tariff costs impacting gross margins - Management is exploring ways to optimize the cost structure and manage supply chain effectively to improve margins [52] Question: Update on robotics and expectations for bookings - Robotics currently accounts for a small percentage of product revenue, with ongoing efforts to develop suitable solutions [83][84] Question: Performance of Enliven and 340B services - Enliven faces headwinds in the retail segment, while 340B remains a compelling part of the specialty business [86][87]

Core Viewpoint - OptimizeRx Corp. is set to discuss its fourth quarter financial results for the period ending December 31, 2025, during a conference call on March 5, 2026, at 4:30 p.m. Eastern Time [1]. Group 1: Conference Call Details - The conference call will be hosted by OptimizeRx management and will include a question-and-answer session [2]. - Participants can join the call via toll-free and international numbers, with a specific conference ID provided [2]. - A replay of the call will be available for 12 months on the OptimizeRx investor relations website [3]. Group 2: Company Overview - OptimizeRx is a leading healthcare technology company that enhances connections between life sciences brands, healthcare professionals (HCPs), and patients [4]. - The company utilizes AI-driven tools, such as the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood® audiences, to facilitate timely and relevant engagement [4]. - OptimizeRx emphasizes privacy-safe, patient-centric technology to ensure impactful interactions that deliver therapies to patients effectively [5].

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Core Viewpoint - Aclarion, Inc. has established an agreement with Source Healthcare to enhance the application of its Nociscan technology in addressing chronic low back pain, aiming to fill a significant gap in pain management solutions [1][2]. Group 1: Agreement and Strategic Expansion - The agreement with Source Healthcare aligns with Aclarion's strategy to expand the use of Nociscan, a non-invasive diagnostic tool for chronic low back pain [2]. - Source Healthcare, led by Dr. Timothy T. Davis, will integrate Nociscan into its multidisciplinary approach, generating real-world evidence to compare Nociscan with traditional anesthetic discography [2][3]. Group 2: Nociscan Technology and Benefits - Nociscan is a non-invasive alternative that objectively measures pain and structural integrity biomarkers in spinal discs, providing insights that traditional methods like MRI and discography do not offer [3][4]. - The technology has shown improved outcomes and lower costs in spinal fusion studies, and this collaboration aims to establish its efficacy in the broader pain management field [3][5]. - Approximately 266 million people globally suffer from chronic low back pain, highlighting the significant market potential for Nociscan [3]. Group 3: Clinical Validation and Growth Strategy - The partnership supports Aclarion's scalable growth strategy while building critical data assets necessary for payer and provider adoption of Nociscan [5]. - Nociscan's ability to provide clarity in diagnosing painful versus non-painful discs is expected to optimize treatment strategies for physicians [6].

Core Viewpoint - Clover Health Investments, Corp. is set to release its financial results for the fourth quarter and full year of 2025 on February 26, 2026, with a management webcast to follow discussing business and financial performance [1]. Group 1: Financial Results Announcement - The financial results will be announced after market close on February 26, 2026 [1]. - A webcast presentation by the company's management will take place at 5:00 p.m. Eastern Time on the same day [1][4]. Group 2: Webcast Details - A live and archived version of the conference call will be available on Clover Health's Investor Relations website for 12 months [2]. - Registration for the webcast can be done through a specific link provided [4]. Group 3: Company Overview - Clover Health is a physician enablement technology company focused on improving healthcare access for Medicare recipients, particularly seniors [3]. - The company utilizes its software platform, Clover Assistant, to aggregate patient data and enhance clinical decision-making, aiming to improve health outcomes [3]. - Clover Health offers PPO and HMO Medicare Advantage plans and extends its technology benefits through its subsidiary, Counterpart Health, to improve patient outcomes and reduce healthcare costs [3].

Core Insights - CareCloud, Inc. has signed an agreement with Memorial Hospital in Marysville, Ohio to implement its HealthLine supply chain management platform, enhancing operational excellence and resource stewardship in community healthcare [1][2] Company Overview - CareCloud is a leader in healthcare technology and AI-powered solutions, focusing on improving financial and operational performance for healthcare providers [9] - The company’s product portfolio includes AI-driven ambulatory, revenue cycle management (RCM), and analytics offerings, with the HealthLine platform being a significant addition following the acquisition of Medsphere in August 2025 [2][9] HealthLine Platform Features - HealthLine provides real-time visibility and control over clinical supply operations, addressing critical operational priorities such as reducing supply waste, improving charge capture accuracy, and freeing clinical staff from manual inventory management tasks [3][4] - The platform is designed to enhance healthcare supply chain management by integrating clinical supply use with financial performance, thereby reducing administrative burdens on clinical staff [5][7] - Key features of HealthLine include point-of-use simplicity, automated charge capture, superior customization, mobility solutions, specialized capabilities for high-complexity areas, and modern architecture [6] Market Context - Healthcare supply chain management has become a strategic priority as organizations face rising supply costs and regulatory requirements for charge capture accuracy, necessitating modern, integrated supply chain platforms [5] - The increasing complexity of healthcare supply chains demands transparency and efficiency, which HealthLine aims to provide [3][4]

Core Insights - Healthcare Triangle, Inc. (HCTI) is participating in the Deal Flow Discovery Conference on January 28-29, 2026, in Atlantic City, New Jersey, where it will present its strategic vision and growth initiatives [1][1][1] Company Overview - HCTI is a leader in digital transformation solutions for healthcare and life sciences, focusing on improving health outcomes through better utilization of data and information technologies [1][1] - The company provides HITRUST Certification for its Cloud and Data Platform, demonstrating high standards for data protection and information security [1][1] Conference Participation - At the conference, HCTI will showcase its expanding portfolio, including healthcare cloud services, AI-driven data platforms, and digital transformation solutions for hospitals and health systems [1][1] - The leadership team will discuss recent milestones and growth initiatives, including an International Acquisition Road Map and proprietary patient engagement tools [1][1] Strategic Focus - HCTI emphasizes AI-led managed services aimed at enhancing efficiency, cost optimization, and business agility in the highly regulated healthcare and life sciences industries [1][1] - The company is focused on cybersecurity and compliance solutions, behavioral healthcare solutions in EMEA, and digital-first healthcare solutions for providers [1][1]

TAMPA, Fla., Jan. 27, 2026 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX: MRAI), a leader in innovative healthcare technology, Pharmacy Benefit Management (PBM) and Third-Party Administration (TPA) services, announced the hiring of Mimi Davis as President of MarpaiRx. Davis, a distinguished leader in the pharmacy services sector, will oversee the strategic expansion and operational scaling of Marpai's pharmacy benefit offerings. Davis joins Marpai from Knipper Health, where she served as E ...